https://www.selleckchem.com/products/OSI-906.html
•There is a concern that renin-angiotensin-aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19).•There no evidence that treatment with RAAS blockers worsens the course of COVID-19.•Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities.•RAAS blockers should be continued in patients with otherwise stable conditions.COVID-19 has officially consumed every nurse leader's time and efforts. The purpose of this article is to share early learnings from the West Coast of the United State
Curtir
Comentario
Compartilhar
